Jason Bryant, general manager of AI platforms at ArisGlobal, and Samuel Wallis, head of case processing at Bristol Myers Squibb, argue that pharmacovigilance teams need a formal measure of trust in validated AI systems — a governance question regulators are now framing across the whole medicines lifecycle.
Shutterstock - Inkoly